Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083538 · ClinicalTrials.gov registry record · Phase 2
Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00083538 is a Phase 2 study that has completed, run by University of Arkansas. The registered enrollment target is 40 participants.
The verdict
NCT00083538, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if vaccination with autologous idiotype- or tumor lysate-pulsed dendritic cells induces the generation of anti-idiotypic and anti-tumor immunologic responses.
Interventions
- DRUG Cyclophosphamide
- DRUG Dexamethasone
- DRUG Cisplatinum
- DRUG Thalidomide
- DRUG Adriamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2001-02 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083538
The ClinicalTrials.gov registry entry for NCT00083538 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00083538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00083538 about?
NCT00083538 is a clinical study titled "Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally". The purpose of this study is to determine if vaccination with autologous idiotype- or tumor lysate-pulsed dendritic cells induces the generation of anti-idiotypic and anti-tumor immunologic responses.
What is the current status of trial NCT00083538?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2001-02. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00083538?
The interventions under investigation include: Cyclophosphamide (DRUG), Dexamethasone (DRUG), Cisplatinum (DRUG), Thalidomide (DRUG), Adriamycin (DRUG).
Who is sponsoring clinical trial NCT00083538?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.